Chiron refuses $4.5bn Novartis offer, later accepts $5.1bn
Stating that the offer is "inadequate," Chiron has refused Novartis's proposal to buy the 57.8% of Chiron (112mm fully diluted common shares) it doesn't already own. The offer was $40 cash per share (a 12% premium), for a total of $4.5bn.
- Includes Contract
- Partial Acquisition
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com